Changes in Sensitivity of Reward and Motor Behavior to Dopaminergic, Glutamatergic, and Cholinergic Drugs in a Mouse Model of Fragile X Syndrome

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Fish, Eric W ^a   Krouse, Michael C ^a   Stringfield, Sierra J ^b   DiBerto, Jeffrey F ^a   Robinson, J Elliott ^a,b   Malanga, C J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; COCAINE; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; TRIHEXYPHENIDYL; TYROSINE 3 MONOOXYGENASE;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINE SYNTHESIS; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ENZYME BLOOD LEVEL; FMR1 GENE; FOREBRAIN; FRAGILE X SYNDROME; GLUTAMATERGIC SYSTEM; IMMUNOREACTIVITY; LOCOMOTION; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REWARD; SELF STIMULATION; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; COCAINE; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCARINIC ANTAGONISTS; PIPERAZINES; PYRIDINES; QUINOLONES; RECEPTOR, METABOTROPIC GLUTAMATE 5; REWARD; TRIHEXYPHENIDYL; TYROSINE 3-MONOOXYGENASE;

EID: 84885770516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077896     Document Type: Article

References (82)

1. Turner G, Webb T, Wake S, Robinson H, (1996) Prevalence of fragile X syndrome. Am J Med Genet 64: 196-197. doi:10.1002/(SICI)1096-8628(19960712)64:1. PubMed: 8826475.
2. Rogers SJ, Wehner DE, Hagerman R, (2001) The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr 22: 409-417. doi:10.1097/00004703-200112000-00008. PubMed: 11773805.
3. Wassink TH, Piven J, Patil SR, (2001) Chromosomal abnormalities in a clinic sample of individuals with autistic disorder. Psychiatr Genet 11: 57-63. doi:10.1097/00041444-200106000-00001. PubMed: 11525418.
4. Reiss AL, Freund L, (1992) Behavioral phenotype of fragile X syndrome: DSM-III-R autistic behavior in male children. Am J Med Genet 43: 35-46. doi:10.1002/ajmg.1320430106. PubMed: 1605210.
5. Cornish K, Sudhalter V, Turk J, (2004) Attention and language in fragile X. Ment Retard Dev Disabil Res Rev 10: 11-16. doi:10.1002/mrdd.20003. PubMed: 14994283.
6. Maes B, Fryns JP, Van Walleghem M, Van den Berghe H, (1994) Cognitive functioning and information processing of adult mentally retarded men with fragile-X syndrome. Am J Med Genet 50: 190-200. doi:10.1002/ajmg.1320500211. PubMed: 8010351.
7. Gallagher A, Hallahan B, (2011) Fragile X-associated disorders: a clinical overview. J Neurol, 259: 401-13. PubMed: 21748281.
8. Feng Y, Zhang F, Lokey LK, Chastain JL, Lakkis L, et al. (1995) Translational suppression by trinucleotide repeat expansion at FMR1. Science 268: 731-734. doi:10.1126/science.7732383. PubMed: 7732383.
9. Garber K, Smith KT, Reines D, Warren ST, (2006) Transcription, translation and fragile X syndrome. Curr Opin Genet Dev 16: 270-275. doi:10.1016/j.gde.2006.04.010. PubMed: 16647847.
10. Krueger DD, Osterweil EK, Chen SP, Tye LD, Bear MF, (2011) Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A 108: 2587-2592. doi:10.1073/pnas.1013855108. PubMed: 21262808.
11. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, et al. (1999) Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94: 185-192. doi:10.1016/S0306-4522(99)00285-7. PubMed: 10613508.
12. Dobkin C, Rabe A, Dumas R, El Idrissi A, Haubenstock H, et al. (2000) Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience 100: 423-429. doi:10.1016/S0306-4522(00)00292-X. PubMed: 11008180.
13. Van Dam D, D'Hooge R, Hauben E, Reyniers E, Gantois I, et al. (2000) Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behav Brain Res 117: 127-136. doi:10.1016/S0166-4328(00)00296-5. PubMed: 11099766.
14. Wang H, Wu LJ, Kim SS, Lee FJ, Gong B, et al. (2008) FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 59: 634-647. doi:10.1016/j.neuron.2008.06.027. PubMed: 18760699.
15. Ventura R, Pascucci T, Catania MV, Musumeci SA, Puglisi-Allegra S, (2004) Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. Behav Pharmacol 15: 433-442. doi:10.1097/00008877-200409000-00018. PubMed: 15343070.
16. Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE, (2002) Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12: 39-46. doi:10.1002/hipo.10005.abs. PubMed: 11918286.
17. McNaughton CH, Moon J, Strawderman MS, Maclean KN, Evans J, et al. (2008) Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behav Neurosci 122: 293-300. doi:10.1037/0735-7044.122.2.293. PubMed: 18410169.
18. Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R, (2012) Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl) 219: 47-58. doi:10.1007/s00213-011-2375-4.
19. Dölen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, et al. (2007) Correction of fragile X syndrome in mice. Neuron 56: 955-962. doi:10.1016/j.neuron.2007.12.001. PubMed: 18093519.
20. Chen L, Toth M, (2001) Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 103: 1043-1050. doi:10.1016/S0306-4522(01)00036-7. PubMed: 11301211.
21. Moy SS, Nadler JJ, Young NB, Nonneman RJ, Grossman AW, et al. (2009) Social approach in genetically engineered mouse lines relevant to autism. Genes Brain Behav 8: 129-142. doi:10.1111/j.1601-183X.2008.00452.x. PubMed: 19016890.
22. Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R, (2005) Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 4: 420-430. doi:10.1111/j.1601-183X.2005.00123.x. PubMed: 16176388.
23. Mineur YS, Huynh LX, Crusio WE, (2006) Social behavior deficits in the Fmr1 mutant mouse. Behav Brain Res 168: 172-175. doi:10.1016/j.bbr.2005.11.004. PubMed: 16343653.
24. Berry-Kravis E, Knox A, Hervey C, (2011) Targeted treatments for fragile X syndrome. J Neurodev Disord 3: 193-210. doi:10.1007/s11689-011-9074-7. PubMed: 21484200.
25. Bear MF, Huber KM, Warren ST, (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370-377. doi:10.1016/j.tins.2004.04.009. PubMed: 15219735.
26. Vanderklish PW, Edelman GM, (2005) Differential translation and fragile X syndrome. Genes Brain Behav 4: 360-384. doi:10.1111/j.1601-183X.2005.00134.x. PubMed: 16098135.
27. Pfeiffer BE, Huber KM, (2007) Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. J Neurosci 27: 3120-3130. doi:10.1523/JNEUROSCI.0054-07.2007. PubMed: 17376973.
28. Volk LJ, Pfeiffer BE, Gibson JR, Huber KM, (2007) Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J Neurosci 27: 11624-11634. doi:10.1523/JNEUROSCI.2266-07.2007. PubMed: 17959805.
29. Nimchinsky EA, Oberlander AM, Svoboda K, (2001) Abnormal development of dendritic spines in FMR1 knock-out mice. J Neurosci 21: 5139-5146. PubMed: 11438589.
30. He CX, Portera-Cailliau C, (2012) The trouble with spines in fragile X syndrome: density, maturity and plasticity. Neuroscience, 251: 120-8. PubMed: 22522472.
31. Cruz-Martín A, Crespo M, Portera-Cailliau C, (2010) Delayed stabilization of dendritic spines in fragile X mice. J Neurosci 30: 7793-7803. doi:10.1523/JNEUROSCI.0577-10.2010. PubMed: 20534828.
32. Pop AS, Levenga J, de Esch CE, Buijsen RA, Nieuwenhuizen IM, et al. (2012) Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology (Berl). PubMed: 23254376.
33. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, et al. (2009) Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A 106: 21377-21382. doi:10.1073/pnas.0903676106. PubMed: 19948956.
34. Nimitvilai S, McElvain MA, Brodie MS, (2013) Reversal of dopamine D2 agonist-induced inhibition of ventral tegmental area neurons by Gq-linked neurotransmitters is dependent on protein kinase C, G protein-coupled receptor kinase, and dynamin. J Pharmacol Exp Ther 344: 253-263. doi:10.1124/jpet.112.199844. PubMed: 23019137.
35. Bear MF, (2005) Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav 4: 393-398. doi:10.1111/j.1601-183X.2005.00135.x. PubMed: 16098137.
36. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, et al. (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31: 127-132. doi:10.1016/j.nbd.2008.04.002. PubMed: 18571098.
37. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP, (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49: 1053-1066. doi:10.1016/j.neuropharm.2005.06.004. PubMed: 16054174.
38. Veeraragavan S, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R, (2011) The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide. Behav Neurosci 125: 783-790. doi:10.1037/a0025202. PubMed: 21942438.
39. Veeraragavan S, Bui N, Perkins JR, Yuva-Paylor LA, Carpenter RL, et al. (2011) Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome. Psychopharmacology (Berl) 217: 143-151. doi:10.1007/s00213-011-2276-6.
40. Gruss M, Braun K, (2004) Age- and region-specific imbalances of basal amino acids and monoamine metabolism in limbic regions of female Fmr1 knock-out mice. Neurochem Int 45: 81-88. doi:10.1016/j.neuint.2003.12.001. PubMed: 15082225.
41. Fulks JL, O'Bryhim BE, Wenzel SK, Fowler SC, Vorontsova E, et al. (2010) Dopamine Release and Uptake Impairments and Behavioral Alterations Observed in Mice that Model Fragile X Mental Retardation Syndrome. Acs Chem Neurosci 1: 679-690. doi:10.1021/cn100032f. PubMed: 21116467.
42. Wang H, Kim SS, Zhuo M, (2010) Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization. J Biol Chem 285: 21888-21901. doi:10.1074/jbc.M110.116293. PubMed: 20457613.
43. Fisch GS, Hao HK, Bakker C, Oostra BA, (1999) Learning and memory in the FMR1 knockout mouse. Am J Med Genet 84: 277-282. doi:10.1002/(SICI)1096-8628(19990528)84:3. PubMed: 10331607.
44. Eliez S, Blasey CM, Freund LS, Hastie T, Reiss AL, (2001) Brain anatomy, gender and IQ in children and adolescents with fragile X syndrome. Brain 124: 1610-1618. doi:10.1093/brain/124.8.1610. PubMed: 11459752.
45. Gothelf D, Furfaro JA, Hoeft F, Eckert MA, Hall SS, et al. (2008) Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP). Ann Neurol 63: 40-51. doi:10.1002/ana.21243. PubMed: 17932962.
46. Hoeft F, Carter JC, Lightbody AA, Cody Hazlett H, Piven J, et al. (2010) Region-specific alterations in brain development in one- to three-year-old boys with fragile X syndrome. Proc Natl Acad Sci U S A 107: 9335-9339. doi:10.1073/pnas.1002762107. PubMed: 20439717.
47. Menon V, Leroux J, White CD, Reiss AL, (2004) Frontostriatal deficits in fragile X syndrome: relation to FMR1 gene expression. Proc Natl Acad Sci U S A 101: 3615-3620. doi:10.1073/pnas.0304544101. PubMed: 14993603.
48. Hoeft F, Hernandez A, Parthasarathy S, Watson CL, Hall SS, et al. (2007) Fronto-striatal dysfunction and potential compensatory mechanisms in male adolescents with fragile X syndrome. Hum Brain Mapp 28: 543-554. doi:10.1002/hbm.20406. PubMed: 17437282.
49. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, et al. (2009) Advances in the treatment of fragile X syndrome. Pediatrics 123: 378-390. doi:10.1542/peds.2008-0317. PubMed: 19117905.
50. Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, et al. (2011) A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology (Berl) 216: 85-90. doi:10.1007/s00213-011-2194-7.
51. Sciamanna G, Tassone A, Mandolesi G, Puglisi F, Ponterio G, et al. (2012) Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia. J Neurosci 32: 11991-12004. doi:10.1523/JNEUROSCI.0041-12.2012. PubMed: 22933784.
52. Threlfell S, Clements MA, Khodai T, Pienaar IS, Exley R, et al. (2010) Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J Neurosci 30: 3398-3408. doi:10.1523/JNEUROSCI.5620-09.2010. PubMed: 20203199.
53. Tanda G, Ebbs AL, Kopajtic TA, Elias LM, Campbell BL, et al. (2007) Effects of muscarinic M1 receptor blockade on cocaine-induced elevations of brain dopamine levels and locomotor behavior in rats. J Pharmacol Exp Ther 321: 334-344. doi:10.1124/jpet.106.118067. PubMed: 17255465.
54. Koós T, Tepper JM, (2002) Dual cholinergic control of fast-spiking interneurons in the neostriatum. J Neurosci 22: 529-535. PubMed: 11784799.
55. Riday TT, Dankoski EC, Krouse MC, Fish EW, Walsh PL, et al. (2012) Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome. J Clin Invest 122: 4544-4554. doi:10.1172/JCI61888. PubMed: 23143301.
56. Ivanco TL, Greenough WT, (2002) Altered mossy fiber distributions in adult Fmr1 (FVB) knockout mice. Hippocampus 12: 47-54. doi:10.1002/hipo.10004.abs. PubMed: 11918288.
57. Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, et al. (2003) RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 37: 417-431. doi:10.1016/S0896-6273(03)00034-5. PubMed: 12575950.
58. Paxinos GT, Franklin KB, (2001) The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic Press.
59. Miliaressis E, Rompre PP, Laviolette P, Philippe L, Coulombe D, (1986) The curve-shift paradigm in self-stimulation. Physiol Behav 37: 85-91. doi:10.1016/0031-9384(86)90388-4. PubMed: 3016774.
60. West MJ, (1999) Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci 22: 51-61. doi:10.1016/S0166-2236(98)01362-9. PubMed: 10092043.
61. Gundersen HJ, Jensen EB, (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229-263. doi:10.1111/j.1365-2818.1987.tb02837.x. PubMed: 3430576.
62. Fish EW, Riday TT, McGuigan MM, Faccidomo S, Hodge CW, et al. (2010) Alcohol, cocaine, and brain stimulation-reward in C57Bl6/J and DBA2/J mice. Alcohol Clin Exp Res 34: 81-89. doi:10.1111/j.1530-0277.2009.01069.x. PubMed: 19860803.
63. Robinson JE, Agoglia AE, Fish EW, Krouse MC, Malanga CJ, (2012) Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine. Behav Brain Res 234: 76-81. doi:10.1016/j.bbr.2012.06.012. PubMed: 22728726.
64. Kenny PJ, Boutrel B, Gasparini F, Koob GF, Markou A, (2005) Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology (Berl) 179: 247-254. doi:10.1007/s00213-004-2069-2. PubMed: 15602687.
65. Baquet ZC, Williams D, Brody J, Smeyne RJ, (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161: 1082-1090. doi:10.1016/j.neuroscience.2009.04.031. PubMed: 19376196.
66. Wise RA, Rompre PP, (1989) Brain dopamine and reward. Annu Rev Psychol 40: 191-225. doi:10.1146/annurev.ps.40.020189.001203. PubMed: 2648975.
67. Mavrikaki M, Nomikos GG, Panagis G, (2010) Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania. Int J Neuropsychopharmacol 13: 541-548. doi:10.1017/S1461145709991143. PubMed: 20047715.
68. Smith WB, Starck SR, Roberts RW, Schuman EM, (2005) Dopaminergic stimulation of local protein synthesis enhances surface expression of GluR1 and synaptic transmission in hippocampal neurons. Neuron 45: 765-779. doi:10.1016/j.neuron.2005.01.015. PubMed: 15748851.
69. Schotanus SM, Chergui K, (2008) Dopamine D1 receptors and group I metabotropic glutamate receptors contribute to the induction of long-term potentiation in the nucleus accumbens. Neuropharmacology 54: 837-844. doi:10.1016/j.neuropharm.2007.12.012. PubMed: 18272187.
70. Huang CC, Yeh CM, Wu MY, Chang AY, Chan JY, et al. (2011) Cocaine withdrawal impairs metabotropic glutamate receptor-dependent long-term depression in the nucleus accumbens. J Neurosci 31: 4194-4203. doi:10.1523/JNEUROSCI.5239-10.2011. PubMed: 21411660.
71. Cheer JF, Heien ML, Garris PA, Carelli RM, Wightman RM, (2005) Simultaneous dopamine and single-unit recordings reveal accumbens GABAergic responses: implications for intracranial self-stimulation. Proc Natl Acad Sci U S A 102: 19150-19155. doi:10.1073/pnas.0509607102. PubMed: 16380429.
72. Taha SA, Fields HL, (2006) Inhibitions of nucleus accumbens neurons encode a gating signal for reward-directed behavior. J Neurosci 26: 217-222. doi:10.1523/JNEUROSCI.3227-05.2006. PubMed: 16399690.
73. English DF, Ibanez-Sandoval O, Stark E, Tecuapetla F, Buzsáki G, et al. (2012) GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons. Nat Neurosci 15: 123-130. PubMed: 22158514.
74. Ebihara K, Yamamoto K, Ueda K, Koshikawa N, Kobayashi M, (2013) Cholinergic interneurons suppress action potential initiation of medium spiny neurons in rat nucleus accumbens shell. Neuroscience 236: 332-344. doi:10.1016/j.neuroscience.2013.01.012. PubMed: 23380504.
75. Grillner P, Berretta N, Bernardi G, Svensson TH, Mercuri NB, (2000) Muscarinic receptors depress GABAergic synaptic transmission in rat midbrain dopamine neurons. Neuroscience 96: 299-307. doi:10.1016/S0306-4522(99)00579-5. PubMed: 10683570.
76. Wan Y, Feng G, Calakos N, (2011) Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J Neurosci 31: 16685-16691. doi:10.1523/JNEUROSCI.2533-11.2011. PubMed: 22090495.
77. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, et al. (2007) Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A 104: 15537-15542. doi:10.1073/pnas.0707484104. PubMed: 17881561.
78. Chen M, Wan Y, Ade K, Ting J, Feng G, et al. (2011) Sapap3 deletion anomalously activates short-term endocannabinoid-mediated synaptic plasticity. J Neurosci 31: 9563-9573. doi:10.1523/JNEUROSCI.1701-11.2011. PubMed: 21715621.
79. Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, et al. (2010) Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology 35: 1500-1509. doi:10.1038/npp.2010.19. PubMed: 20393458.
80. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, et al. (2012) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 3: 1080. doi:10.1038/ncomms2045. PubMed: 23011134.
81. Bellone C, Lüscher C, (2005) mGluRs induce a long-term depression in the ventral tegmental area that involves a switch of the subunit composition of AMPA receptors. Eur J Neurosci 21: 1280-1288. doi:10.1111/j.1460-9568.2005.03979.x. PubMed: 15813937.
82. Lovaas OI, Smith T, (1989) A comprehensive behavioral theory of autistic children: paradigm for research and treatment. J Behav Ther Exp Psychiatry 20: 17-29. doi:10.1016/0005-7916(89)90004-9. PubMed: 2671048.